Hypersensitivity reactions to trimetrexate

Jean L. Grem, Susan A. King, Mary E. Costanza, Thomas D. Brown

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Trimetrexate is a nonclassical antifol currently being tested for efficacy in cancer patients and as an antiparasitic agent against Pneumocystis carinii pneumonia in AIDS patients. We have now received the first reports of hypersensitivity reactions in Phase II cancer trials. Two types of reactions were noted. The most severe reaction, immediate hypotension with loss of consciousness, occurred in only one patient. Four other patients exhibited an immediate systemic effect with one or more of the following symptoms: facial flushing, fever, shaking, pruritus, bronchospasm, periorbital edema, and difficulty in swallowing. Immediate hypersensitivity should now be considered a known side effect of trimetrexate therapy, occurring in < 2% of patients.

Original languageEnglish (US)
Pages (from-to)211-214
Number of pages4
JournalInvestigational New Drugs
Volume8
Issue number2
DOIs
StatePublished - May 1 1990

Fingerprint

Trimetrexate
Hypersensitivity
Antiparasitic Agents
Immediate Hypersensitivity
Bronchial Spasm
Pneumocystis Pneumonia
Unconsciousness
Pruritus
Deglutition
Hypotension
Edema
Neoplasms
Acquired Immunodeficiency Syndrome
Fever

Keywords

  • hypersensitivity
  • trimetrexate

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Hypersensitivity reactions to trimetrexate. / Grem, Jean L.; King, Susan A.; Costanza, Mary E.; Brown, Thomas D.

In: Investigational New Drugs, Vol. 8, No. 2, 01.05.1990, p. 211-214.

Research output: Contribution to journalArticle

Grem, JL, King, SA, Costanza, ME & Brown, TD 1990, 'Hypersensitivity reactions to trimetrexate', Investigational New Drugs, vol. 8, no. 2, pp. 211-214. https://doi.org/10.1007/BF00177263
Grem, Jean L. ; King, Susan A. ; Costanza, Mary E. ; Brown, Thomas D. / Hypersensitivity reactions to trimetrexate. In: Investigational New Drugs. 1990 ; Vol. 8, No. 2. pp. 211-214.
@article{a523a92bd8ff4917be046559785e9105,
title = "Hypersensitivity reactions to trimetrexate",
abstract = "Trimetrexate is a nonclassical antifol currently being tested for efficacy in cancer patients and as an antiparasitic agent against Pneumocystis carinii pneumonia in AIDS patients. We have now received the first reports of hypersensitivity reactions in Phase II cancer trials. Two types of reactions were noted. The most severe reaction, immediate hypotension with loss of consciousness, occurred in only one patient. Four other patients exhibited an immediate systemic effect with one or more of the following symptoms: facial flushing, fever, shaking, pruritus, bronchospasm, periorbital edema, and difficulty in swallowing. Immediate hypersensitivity should now be considered a known side effect of trimetrexate therapy, occurring in < 2{\%} of patients.",
keywords = "hypersensitivity, trimetrexate",
author = "Grem, {Jean L.} and King, {Susan A.} and Costanza, {Mary E.} and Brown, {Thomas D.}",
year = "1990",
month = "5",
day = "1",
doi = "10.1007/BF00177263",
language = "English (US)",
volume = "8",
pages = "211--214",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Hypersensitivity reactions to trimetrexate

AU - Grem, Jean L.

AU - King, Susan A.

AU - Costanza, Mary E.

AU - Brown, Thomas D.

PY - 1990/5/1

Y1 - 1990/5/1

N2 - Trimetrexate is a nonclassical antifol currently being tested for efficacy in cancer patients and as an antiparasitic agent against Pneumocystis carinii pneumonia in AIDS patients. We have now received the first reports of hypersensitivity reactions in Phase II cancer trials. Two types of reactions were noted. The most severe reaction, immediate hypotension with loss of consciousness, occurred in only one patient. Four other patients exhibited an immediate systemic effect with one or more of the following symptoms: facial flushing, fever, shaking, pruritus, bronchospasm, periorbital edema, and difficulty in swallowing. Immediate hypersensitivity should now be considered a known side effect of trimetrexate therapy, occurring in < 2% of patients.

AB - Trimetrexate is a nonclassical antifol currently being tested for efficacy in cancer patients and as an antiparasitic agent against Pneumocystis carinii pneumonia in AIDS patients. We have now received the first reports of hypersensitivity reactions in Phase II cancer trials. Two types of reactions were noted. The most severe reaction, immediate hypotension with loss of consciousness, occurred in only one patient. Four other patients exhibited an immediate systemic effect with one or more of the following symptoms: facial flushing, fever, shaking, pruritus, bronchospasm, periorbital edema, and difficulty in swallowing. Immediate hypersensitivity should now be considered a known side effect of trimetrexate therapy, occurring in < 2% of patients.

KW - hypersensitivity

KW - trimetrexate

UR - http://www.scopus.com/inward/record.url?scp=0025329970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025329970&partnerID=8YFLogxK

U2 - 10.1007/BF00177263

DO - 10.1007/BF00177263

M3 - Article

C2 - 2143501

AN - SCOPUS:0025329970

VL - 8

SP - 211

EP - 214

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -